To evaluate the safety and effectiveness ofvorapaxar in secondary prevention of patients with an acute myocardial infarction (AMI) using the results ofthe thrombin receptor antagonists in the secondary prevention of atheroscleroticthromboischemic events and myocardial infarction hemolysis (TIMI50) test, a TIMI risk score for secondaryprevention (TRS2°P) score was developed to predictlong-term recurrent cardiovascular (CV) events [34, 35]. The gene discussed is F2R; the disease is myocardial infarction.